^
BIOMARKER:
MET amplification
i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
MET amplification
NSCLC
crizotinib
Sensitive
:
A2
Tumori - 3wk
MET amplification
Gastric Adenocarcinoma
crizotinib
Sensitive
:
C3
Target Oncol - 3wk
MET amplification
GastroEsophageal Cancer
crizotinib
Sensitive
:
C3
Target Oncol - 3wk
MET amplification
LUAD
crizotinib
Sensitive
:
C3
Tumori - 3wk
MET amplification
Gastroesophageal Junction Adenocarcinoma
AMG 102
Resistant
:
B
MET amplification
Gastric Adenocarcinoma
AMG 102
Resistant
:
B
MET amplification
NSCLC
crizotinib + bevacizumab
Sensitive
:
C2
MET amplification
NSCLC
SCC244
Sensitive
:
C2
MET amplification
NSCLC
gefitinib + CT053PTSA
Sensitive
:
C2
MET amplification
NSCLC
osimertinib + HMPL-504
Sensitive
:
C2
MET amplification
Lung Cancer
tepotinib
Sensitive
:
C2
MET amplification
NSCLC
APL-101
Sensitive
:
C2
MET amplification
NSCLC
crizotinib + osimertinib
Sensitive
:
C2
MET amplification
NSCLC
capmatinib
Sensitive
:
C2
MET amplification
Gastric Cancer
HMPL-504
Sensitive
:
C2
MET amplification
RCC
crizotinib
Sensitive
:
C2
MET amplification
NSCLC
U3-1402
Sensitive
:
C3
MET amplification
NSCLC
Immunotherapy
Sensitive
:
C3
MET amplification
Gallbladder Cancer
crizotinib
Sensitive
:
C3
MET amplification
NSCLC
c-MET inhibitor
Sensitive
:
C3
MET amplification
CRC
TPX-0022
Sensitive
:
C3
MET amplification
Gastric Cancer
TPX-0022
Sensitive
:
C3
MET amplification
NSCLC
gefitinib + HMPL-504
Sensitive
:
C3
MET amplification
NSCLC
erlotinib
Resistant
:
C3
MET amplification
Solid Tumor
TQ-B3101
Sensitive
:
C3
MET amplification
LUAD
crizotinib + osimertinib
Sensitive
:
C3
MET amplification
NSCLC
gefitinib
Resistant
:
C3
MET amplification
CRC
cetuximab
Resistant
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our